IBDEI0Q8 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11785,0)
 ;;=N08.^^46^573^21
 ;;^UTILITY(U,$J,358.3,11785,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11785,1,3,0)
 ;;=3^Glomerular disorders in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,11785,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,11785,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,11786,0)
 ;;=C90.00^^46^574^10
 ;;^UTILITY(U,$J,358.3,11786,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11786,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,11786,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,11786,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,11787,0)
 ;;=C90.01^^46^574^9
 ;;^UTILITY(U,$J,358.3,11787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11787,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,11787,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,11787,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,11788,0)
 ;;=C90.02^^46^574^8
 ;;^UTILITY(U,$J,358.3,11788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11788,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,11788,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,11788,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,11789,0)
 ;;=E11.29^^46^574^22
 ;;^UTILITY(U,$J,358.3,11789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11789,1,3,0)
 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,11789,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,11789,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,11790,0)
 ;;=E11.21^^46^574^21
 ;;^UTILITY(U,$J,358.3,11790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11790,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,11790,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,11790,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,11791,0)
 ;;=E11.22^^46^574^20
 ;;^UTILITY(U,$J,358.3,11791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11791,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,11791,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,11791,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,11792,0)
 ;;=E10.29^^46^574^19
 ;;^UTILITY(U,$J,358.3,11792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11792,1,3,0)
 ;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,11792,1,4,0)
 ;;=4^E10.29
 ;;^UTILITY(U,$J,358.3,11792,2)
 ;;=^5002591
 ;;^UTILITY(U,$J,358.3,11793,0)
 ;;=E10.21^^46^574^18
 ;;^UTILITY(U,$J,358.3,11793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11793,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,11793,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,11793,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,11794,0)
 ;;=E10.22^^46^574^17
 ;;^UTILITY(U,$J,358.3,11794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11794,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,11794,1,4,0)
 ;;=4^E10.22
 ;;^UTILITY(U,$J,358.3,11794,2)
 ;;=^5002590
 ;;^UTILITY(U,$J,358.3,11795,0)
 ;;=D59.3^^46^574^3
 ;;^UTILITY(U,$J,358.3,11795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11795,1,3,0)
 ;;=3^Hemolytic-uremic syndrome
 ;;^UTILITY(U,$J,358.3,11795,1,4,0)
 ;;=4^D59.3
 ;;^UTILITY(U,$J,358.3,11795,2)
 ;;=^55823
 ;;^UTILITY(U,$J,358.3,11796,0)
 ;;=D69.0^^46^574^4
 ;;^UTILITY(U,$J,358.3,11796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11796,1,3,0)
 ;;=3^Henoch-Schoeniein Purpura
 ;;^UTILITY(U,$J,358.3,11796,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,11796,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,11797,0)
 ;;=M30.0^^46^574^12
